KYTHERA Biopharmaceuticals, Inc. (KYTHERA) announced that it has initiated a firstinhuman, proofofconcept study evaluating the safety, tolerability, persistence and histological effects of ATX104, a lightactivated facial contouring agent.
“We are very excited to move ATX104 into the clinic,” said Patricia Walker, MD, PhD, KYTHERAs Chief Medical Officer. “In preclinical testing, KYTHERAs proprietary photofiller demonstrated improved [...]

Treating seconddegree burns with a nanoemulsion lotion sharply curbs bacterial growth and reduces inflammation that otherwise can jeopardize recovery, University of Michigan scientists have shown in initial laboratory studies.
UM burn surgeon Mark R. Hemmila, M.D., reports today at the Interscience Conference for Antimicrobial Agents and Chemotherapy on results achieved with a nanoemulsion developed at UM [...]

Thallion Pharmaceuticals Inc. (TSXTLN) announced that it has suspended patient enrollment in its Phase II trial evaluating TLN232 as a treatment for metastatic melanoma, due to an ongoing dispute with the licensor. A binding arbitration proceeding has been initiated and Thallion will reevaluate the status of the program based on the outcome of the adjudication. [...]

A shocking four out of every ten people who suffer from a skin disease in the UK have been bullied as a result of their condition, a new snapshot survey reveals.
23% said that they had suffered from an isolated incident of bullying, with a further 18% revealing that they suffered from regular bullying from [...]

Today sees the European launch of the first topical calcineurin inhibitor to be approved for the maintenance treatment of eczema to prevent flares and prolong flarefree intervals. PROTOPIC ointment (tacrolimus monohydrate) is already licensed to treat moderate and severe eczema (atopic dermatitis), often involving the treatment of flares as and when they occur.* It [...]